New lung cancer test could accurately guide treatment for people with lung cancer
by Anil Kumar

In the two largest clinical studies ever conducted on the molecular genetics of lung cancer, an international team led by scientists at the University of California, San Francisco (UCSF) has demonstrated that an available molecular test can predict the likelihood of death from early-stage lung cancer more accurately than conventional methods.
The work may eventually help improve the odds of survival for hundreds of thousands of patients each year.
Reported this week in The Lancet, the two studies demonstrated how the test, which measures the activity of fourteen genes in cancerous tissue, improves the accuracy of prognosis. This in turn could guide treatments for patients with the most common form of the disease, non-squamous non-small cell lung cancer.
The two independent clinical trials included one blinded study involving the analysis of tissue samples from 433 people with early-stage lung cancer in northern California and another study involving 1,006 people with early-stage lung cancer in China. In both trials, the team showed that the test could accurately predict whether the odds of death within five years of surgery to remove a lung cancer were low, intermediate, or high.
"It's quite exciting," said David Jablons, MD, the Ada Distinguished Professor in Thoracic Oncology and leader of the Thoracic Oncology Program at the Helen Diller Family Comprehensive Cancer Center at UCSF. "This has the potential to help hundreds of thousands of people every year survive longer." Jablons co-led the study with Michael Mann, MD, a UCSF Associate Professor of Cardiothoracic Surgery.
Today, doctors assess early-stage lung cancers by their size, location and microscopic appearance. This information, known as staging, is then used to guide the use of additional treatment following surgery. If doctors could more precisely gauge prognosis, more people who might benefit from additional therapy could receive it immediately after surgery, before any residual cancer has had a chance to grow.
Evidence from other studies suggests that chemotherapy given in early-stage lung cancer helps thwart recurrence when there is evidence of lymph node involvement. Such involvement increases the risk of other, undetectable metastasis.
The scientists plan to design a large clinical trial that would seek to confirm that using the algorithm to guide therapy helps people with lung cancer survive longer.
The study conducted in China is the first major clinical trial result to emerge from the China Clinical Trials Consortium (CCTC), a collaboration between hospitals and universities across mainland China that was founded with the help of leaders from the UCSF Thoracic Oncology Program to confront the epidemic of lung cancer in China.
"The CCTC represents a revolutionary new collaborative approach to clinical research among Chinese and Western experts," said Mann. "It is fitting that this body's first major effort may support a molecular personalization of lung cancer care, and yield one of the first examples that fundamental tumor biology reaches across ethnic lines and can be used to try to improve outcomes for a large percentage of patients."
(Anil Kumar -- sub-editor compiled and published
New lung cancer test could accurately guide treatment for people with lung cancer at HealthNewsTrack on January 26, 2012 sourced from University of California, San Francisco - http://www.ucsf.edu/)
Lung Cancer - recent articles and current news stories:
-
Postoperative radiotherapy does not improve survival in lung cancer patients-
20% reduction in lung cancer mortality with low dose CT vs chest X ray-
Gene expression changes in nasal cells may help identify lung cancer-
Genetic test for lung cancer risk prompts smokers to quitLung Cancer article/news source:
Read more health articles from
University of California, San Francisco and
health articles from USA.
Lung Cancer - search related terms:
Cancer,
Cardiothoracic Surgery,
Chemotherapy,
Lung,
Lung cancer,
Molecular test,
Thoracic Oncology,
Lung Cancer books,
Searched keywords: topic:lung_cancer (10),
Mission
Health Newstrack is dedicated to serve recent and updated health & medical research, events/news, views/reviews to its subscribers and free access to general public, health & medical professionals, and other health seekers worldwide online with a user-friendly system.
Subscribe to Health News by Email
Current news
New lung cancer test predicts survival -- Clinical studies in US and China show molecular test could more accurately guide treatment for people with lung cancer
About Lung CancerLung cancer is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. There are two kinds of lung cancers, primary and secondary. Primary lung cancer (also called adenocarcinoma) starts in the lung itself. Primary lung cancer is divided into small cell lung cancer and non-small cell lung cancer, depending on how the cells look under the microscope. Secondary lung cancer is cancer that starts somewhere else in the body (for example, the breast or colon) and spreads to the lungs.